🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Dr. Agarwal's Health Care Limited AGARWALEYE NSEPHARMA

Healthcare · Medical Instruments & Supplies · India
https://www.dragarwals.co.in
Company Profile ↓
₹464.50
+3.31% 1Y
Mkt Cap₹14,725.87 Cr
P/E99.89
P/B7.47
52W High₹560.70
52W Low₹406.55
Book Value₹63.93
EPS (TTM)₹4.65

Company Overview

Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 12.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 27.0% CAGR over the past five years.

Healthy Margins

Operating margin of 15.0% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹2,080.08 Cr (+21.6% YoY); net profit ₹133.19 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +26.0%, earnings +49.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 27.0%, profit CAGR 12.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:26.96%
1 Year:26.00%

Compounded Profit Growth

5 Years:12.28%
1 Year:49.50%

Stock Price Performance

1 Year:+3.31%
6 Months:+0.73%
3 Months:-4.38%
1 Month:-7.18%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 38% of range
₹406.55 ₹560.70
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)36.52 · Neutral
Price Performance
1M-7.18%
3M-4.38%
6M+0.73%
1Y+3.31%
Valuation vs Sector

P/E of 99.89 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 27.0% over 5 years.
  • Profit CAGR of 12.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 99.9.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
99.89
Industry PE
36.43
Forward P/E
55.17
PEG Ratio
-
Book Value
₹63.93
Price to Book
7.47
P/S
6.86
EV/EBITDA
31.45
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
26.96%
Profit 5Y
12.28%
Revenue (YoY)
26.00%
Earnings (YoY)
49.50%

Profitability & Returns

ROCE
9.74%
ROE
6.58%
ROA
3.38%
Profit Margin
6.72%
Op Margin
15.00%
Gross Margin
43.61%
EPS (Latest Qtr)
₹1.42
EPS (TTM)
₹4.65

Balance Sheet & Liquidity

Debt/Equity
0.50
Quick Ratio
1.04
Current Ratio
1.24
Debt
₹1,066.20 Cr
Total Assets
₹3,941.75 Cr
Current Assets
₹572.97 Cr
Working Capital
₹111.49 Cr

Ownership

Promoter Holding
62.84%
Chg in Prom Hold
-5.01%
FII / Inst Holding
27.68%
Chg in FII Hold
0.50%

Financial Snapshot

Enterprise Value
₹14,725.87 Cr
Total Revenue (TTM)
₹2,206.68 Cr
EBITDA
₹502.27 Cr
Free Cash Flow
₹58.41 Cr
Operating Cash Flow
₹518.99 Cr
Shares Outstanding
₹31.70 Cr
Gross Margin
43.61%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AGARWALEYE Dr. Agarwal's Health Care Limited NSEPHARMA 464.50 99.89 ₹14,725.87 Cr 0.00% 9.74% 6.58% 26.96% 12.28%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 333.00 Cr349.00 Cr403.00 Cr417.00 Cr430.72 Cr460.22 Cr487.42 Cr-529.86 Cr564.11 Cr614.02 Cr
Cost of Revenue ------179.96 Cr178.45 Cr196.72 Cr196.76 Cr218.38 Cr
Gross Profit ------307.46 Cr320.24 Cr333.14 Cr367.35 Cr395.64 Cr
Operating Expenses 244.00 Cr241.00 Cr300.00 Cr310.00 Cr--242.55 Cr251.96 Cr257.79 Cr282.56 Cr303.54 Cr
Operating Income 46.00 Cr61.00 Cr48.00 Cr50.00 Cr56.63 Cr70.60 Cr64.91 Cr-75.35 Cr84.79 Cr92.10 Cr
EBITDA 89.00 Cr108.00 Cr104.00 Cr107.00 Cr127.52 Cr143.92 Cr141.25 Cr-154.64 Cr175.38 Cr176.82 Cr
Interest Expense 22.00 Cr27.00 Cr27.00 Cr28.00 Cr28.35 Cr25.01 Cr24.70 Cr-21.13 Cr22.08 Cr23.37 Cr
Pretax Income 36.00 Cr54.00 Cr27.00 Cr33.00 Cr40.99 Cr58.52 Cr53.60 Cr-64.76 Cr76.62 Cr75.14 Cr
Tax Provision 13.32 Cr12.96 Cr8.91 Cr11.88 Cr12.75 Cr15.97 Cr15.54 Cr-21.13 Cr26.66 Cr20.12 Cr
Net Income 23.00 Cr41.00 Cr18.00 Cr21.00 Cr22.34 Cr32.57 Cr30.05 Cr-33.74 Cr39.71 Cr45.23 Cr
Diluted EPS ----0.711.030.95-1.061.241.42

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 531.00 Cr471.00 Cr-1,016.48 Cr1,327.67 Cr1,711.00 Cr2,080.08 Cr
Cost of Revenue ---558.55 Cr728.57 Cr635.37 Cr751.89 Cr
Gross Profit ---457.93 Cr599.10 Cr1,075.63 Cr1,328.19 Cr
Operating Expenses 407.00 Cr387.00 Cr-304.38 Cr397.25 Cr849.99 Cr1,034.86 Cr
Operating Income 31.00 Cr-10.00 Cr-153.55 Cr201.85 Cr225.64 Cr293.33 Cr
EBITDA 124.00 Cr85.00 Cr-283.86 Cr406.56 Cr499.38 Cr615.34 Cr
Interest Expense 54.00 Cr44.00 Cr-71.97 Cr95.62 Cr108.79 Cr90.46 Cr
Pretax Income -11.00 Cr-48.00 Cr-83.59 Cr140.57 Cr159.85 Cr248.64 Cr
Tax Provision -9.02 Cr-10.08 Cr--19.64 Cr45.52 Cr49.51 Cr80.50 Cr
Net Income -21.00 Cr-59.00 Cr-94.10 Cr83.06 Cr83.46 Cr133.19 Cr
Diluted EPS ---2.982.632.784.18

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 751.00 Cr787.00 Cr-1,825.17 Cr2,752.82 Cr3,671.57 Cr3,941.75 Cr
Current Assets ---310.18 Cr758.58 Cr794.07 Cr572.97 Cr
Cash & Equivalents ---126.98 Cr111.75 Cr103.61 Cr90.55 Cr
Inventory ---36.04 Cr51.90 Cr80.27 Cr94.03 Cr
Receivables ---76.33 Cr96.81 Cr123.56 Cr160.91 Cr
Total Liabilities ---1,166.10 Cr1,373.31 Cr1,744.75 Cr1,822.05 Cr
Current Liabilities ---301.31 Cr399.80 Cr477.76 Cr461.48 Cr
Long Term Debt ---305.60 Cr309.62 Cr157.29 Cr133.30 Cr
Total Debt 162.00 Cr185.00 Cr-857.35 Cr966.44 Cr960.91 Cr1,066.20 Cr
Total Equity 249.00 Cr184.00 Cr-629.56 Cr1,339.41 Cr1,866.59 Cr2,025.46 Cr
Shares Outstanding ---31.59 Cr31.59 Cr31.59 Cr31.68 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 103.00 Cr99.00 Cr-233.11 Cr346.00 Cr357.13 Cr518.99 Cr
Investing Cash Flow -85.00 Cr-46.00 Cr--509.08 Cr-913.91 Cr-750.33 Cr-308.45 Cr
Financing Cash Flow -73.00 Cr-37.00 Cr-303.34 Cr552.68 Cr381.85 Cr-220.39 Cr
Capital Expenditure -201.00 Cr-33.00 Cr--157.80 Cr-232.33 Cr-320.90 Cr-460.58 Cr
Free Cash Flow -98.00 Cr66.00 Cr-75.31 Cr113.67 Cr36.23 Cr58.41 Cr
Net Change in Cash -56.00 Cr17.00 Cr-27.36 Cr-15.23 Cr-11.35 Cr-9.85 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---45.1%45.1%62.9%63.9%
Operating Margin % 5.8%-2.1%-15.1%15.2%13.2%14.1%
Net Margin % -4.0%-12.5%-9.3%6.3%4.9%6.4%
ROE % -8.4%-32.1%-14.9%6.2%4.5%6.6%
ROCE % ---10.1%8.6%7.1%8.4%

Shareholding Pattern

Insiders
62.84%
Institutions
27.68%
Public Float
74.47%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AGARWALEYE

Google News Sat, 19 Sep 2026

AGARWALEYE Stock Price and Chart — NSE:AGARWALEYE - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE44WjdDbVdxRXlzNVpsazhhd01Cbk1zTnJaeV8xVEIyMEVzeEtGWkMtd2lDZWJiT295RGpDZFFodlJoMVJPM3BMWFR1a1JOMjJRTjItNzIwZ3k3X3V5U1ZOUw?oc=5" target="_blank">AGARWALEYE Stock Price and Chart — NS…

Google News Fri, 22 May 2026

Dr Agarwal's Health Care Ltd (NSE:AGARWALEYE) Full Year 2026 Earnings Call Highlights: Record ... - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQRDdyaWJkcDNOcllmWEJmeEJBX2ZUMUVkSGF5Um1CZFdFNDRXOUhmcHZUekNiSl9rdlJDVnB6am5DNFlLUWFOc05QSGhwcXJ5dTNITU1jeERUOG1scWVPMmc5R2pxNHlmQUFka2lwN0JCdktESTExOVR6NmkwNjRzaEtXV2Q4ZEEyaXZ6Y0…

Google News Fri, 07 Aug 2026

₹582 - That's What Analysts Think Dr. Agarwal's Health Care Limited (NSE:AGARWALEYE) Is Worth After These Results - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPdzdQWjBYN014UUxpcWJJVmN1TWhBN2h3RVBqM1JoZTRHVV9GcEUyWWtaa0xoNHIyU2o0czBDZ3pfcV85a0RvTnFRdzEtSURMTnl4NXV4RmkwYlZYc3RpNS1mTGgydm4wd3dUQnBpaUxRcXVPbkRfUnBjaF9sMk51V1lueVV6N3d4emQ4Mk…

Google News ue, 20 Oct 2026

Agarwal's Health Care (NSE:AGARWALEYE): What Does the Amalgamation Scheme Effective Date Mean? - Kalkine India

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPeUxQSXA0THZ5MDBVbzVnS0Rja0dmdnR4MnZ0UHI1eFJDUGQyMlZFVTJQUVRNeVE1OEhIU3h4bXZBMy1nUngyTC1hSVR3c1ZxYzRCUHNQcmpacmdYNUpnaE91RWJjZklhMEhmQjk5dkpTMlg0Y3U2LVRtVTZoUXF6a1hVMmJvclQtV3JaY2…

Google News Mon, 20 Apr 2026

DRAGARWQ Stock Price and Chart — NSE:DRAGARWQ - TradingView

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9qendJSS15Q1d5Y1VWYjJocTRYR1MtcHB5cVRsYzBIQ1lXRHpVbGltOU56S0lfNTEzbjllVTA5VmV3RU9rRVlHSFNpQTlfcUtTRmktTElhUFZZNzc3REE?oc=5" target="_blank">DRAGARWQ Stock Price and Chart — NSE:DRA…

Google News hu, 13 Aug 2026

TPG, Temasek Sell 13% in Dr Agarwals for ₹2,008 Cr - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE5jRGZyY2ZBZHNhUUhKR19tRFZYS1phaTcwS2JqOE8tQ3V0eTYxeHgtdTVwVmp1UUNlNUJGenVTUzBpYWR5SWpDTV81UGNrajZWUWRhRE1qTXBEMVF4cGtuYWtqQWdjOXNwTHBjSjJTR2FkT1BtLTRtMGpYUQ?oc=5" target="_blank">T…

AGARWALEYE — Frequently Asked Questions

What is the current share price of Dr. Agarwal's Health Care Limited (AGARWALEYE)?

As of 2026-10-23 04:58 IST, Dr. Agarwal's Health Care Limited (AGARWALEYE) trades at ₹464.50 on NSE. Its 52-week range is ₹406.55 to ₹560.70.

What is the market capitalisation of AGARWALEYE?

Dr. Agarwal's Health Care Limited (AGARWALEYE) has a market capitalisation of ₹14,725.87 Cr on NSE.

What is the P/E ratio of AGARWALEYE?

AGARWALEYE trades at a trailing price-to-earnings (P/E) ratio of 99.89. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 7.47.

What is the return on equity (ROE) of AGARWALEYE?

AGARWALEYE has a return on equity (ROE) of 6.58%. Its return on capital employed (ROCE) is 9.74%.

Is AGARWALEYE a good stock to buy?

This page provides a data-driven analysis of Dr. Agarwal's Health Care Limited (AGARWALEYE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space